Outpatiented · Case Knowledge
Two different classes of osteoporosis medication that work through completely opposite mechanisms. What the difference is, who qualifies for each, what a fragility fracture changes, and what the system often does not explain before choosing a treatment.
The Core Difference
Bone is not static tissue. It is constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts. In osteoporosis, breakdown outpaces building, the result is reduced bone density and increased fracture risk. The two main treatment classes address this imbalance from opposite ends.
Understanding the mechanism matters because it determines who each medication is best suited for, what to expect from it, and what comes after.
A fragility fracture changes
your risk category regardless of what your T-score says.
Most people are not told this.
The Fragility Fracture Rule
DEXA scan T-scores are a tool for estimating fracture risk. They are not the final word on clinical risk category. A T-score alone tells you about bone density. It does not tell you about bone quality, microarchitecture, fall risk, or the most important signal of all: whether your bones have already fractured under conditions that should not have caused a fracture.
A fragility fracture is a fracture that occurs from low-impact trauma, a fall from standing height or less, or in some cases no identifiable trauma at all. Examples include vertebral compression fractures found incidentally on imaging, hip fracture from a minor fall, or wrist fracture from catching yourself. A pubic ramus fracture found on imaging without a significant trauma history is a fragility fracture.
Current osteoporosis guidelines, including those from the American Association of Clinical Endocrinology and the National Osteoporosis Foundation, recognize that a fragility fracture reclassifies a person to clinical osteoporosis even if their DEXA T-score does not reach the diagnostic threshold of -2.5. The fracture is direct evidence that bone strength has failed under conditions it should have handled. That is the clinical definition of osteoporosis in practice, not a number on a scan.
Guidelines specifically support anabolic-first treatment, teriparatide or abaloparatide before bisphosphonates, not after, for patients at very high fracture risk. The criteria for very high risk include: a fragility fracture within the past 12 to 24 months, T-score at or below -3.0 at any site, multiple fractures, or fracture while on antiresorptive therapy. A person with a recent fragility fracture and a femoral neck T-score of -2.9 clearly meets this threshold. They do not need to try bisphosphonates first. Anabolic-first is the guideline-supported starting point.
Teriparatide has a 2-year lifetime cap on use, based on animal studies showing osteosarcoma risk at very high doses over extended periods (this risk has not been demonstrated in humans at clinical doses, but the cap remains in place). After the 2-year course, the bone density gains made during teriparatide are maintained and extended by transitioning to an antiresorptive agent, typically a bisphosphonate or denosumab. Stopping without an antiresorptive follow-on leads to rapid loss of the gains. The sequence is: teriparatide builds, antiresorptive locks it in.
Before attributing any fracture to osteoporosis and initiating therapy, secondary causes of bone loss and pathologic fracture should be excluded. For a pubic ramus fracture specifically, the differential includes metastatic disease, multiple myeloma, and metabolic bone disease beyond primary osteoporosis. Standard secondary workup: comprehensive metabolic panel, 25-OH vitamin D, PTH, TSH, complete blood count, SPEP (serum protein electrophoresis to screen for myeloma), and 24-hour urine calcium. This workup should precede starting teriparatide and is part of what an endocrinologist or rheumatologist will confirm.
Teriparatide is contraindicated in people with prior skeletal radiation therapy, Paget's disease of bone, unexplained elevations in alkaline phosphatase, bone malignancy or metastases to bone, hypercalcemia, and in pediatric patients with open growth plates. If any of these apply, teriparatide is not appropriate regardless of fracture risk.
If you have had radiation therapy for cancer that included any bone in the field. This is the most important item to raise with your prescriber before initiating teriparatide. The contraindication is firm.
None of these contraindications are particularly common in the typical osteoporosis patient, but they are worth confirming before treatment begins. An endocrinologist initiating teriparatide will check these systematically.
Getting Teriparatide Prescribed
Teriparatide is an anabolic agent that requires prior authorization from insurance, is significantly more expensive than bisphosphonates, and is typically initiated by a specialist rather than a primary care provider. This creates access friction that patients frequently encounter, even when teriparatide is the appropriate clinical choice.
Primary care providers and physician assistants can prescribe teriparatide, but many are not comfortable initiating an anabolic agent independently. If your primary provider is hesitant, the most productive path is a referral to endocrinology or rheumatology rather than a conflict. Specialists in those fields manage this regularly and can also handle the prior authorization documentation, which is where many prescriptions fail.
Insurance prior authorization for teriparatide typically requires documentation of: a qualifying T-score, a fragility fracture history, or failure of or intolerance to bisphosphonate therapy. A fragility fracture is usually sufficient as a standalone qualifier for very high risk classification. Having the specialist document the fracture history, the T-score, and the guideline rationale for anabolic-first therapy in their notes gives your insurer what they need to approve it. A specialist's written recommendation is significantly more effective than a patient request alone.
Brand-name Forteo is expensive at full price. The Alvogen generic teriparatide, which entered the market after Lilly's patent expired, is bioequivalent and covered under many Medicare Part D plans at a significantly lower cost. If you are on a Part D plan, ask specifically whether Alvogen generic teriparatide is on your formulary before the prescription is written. Having the prescriber specify the generic on the script reduces coverage denial risk. Manufacturer patient assistance programs exist for Forteo for those who do not qualify for generic coverage.
General consumer telehealth platforms (Teladoc, MDLive, etc.) do not typically initiate specialist-level medications like teriparatide. The more reliable remote route is a virtual visit with an endocrinologist or rheumatologist through a hospital-affiliated telehealth program, or a bone health clinic that offers virtual appointments. Once a specialist has initiated the prescription and handled the prior authorization, subsequent management can often continue with your primary provider. Specialty pharmacies handle teriparatide dispensing and injection pen supply and typically ship directly.
Questions People Actually Ask
Do I have to try bisphosphonates before I can get teriparatide?
No, not if you meet the criteria for very high fracture risk. The older treatment paradigm was bisphosphonate-first for everyone, with anabolic agents reserved for failures. Current guidelines have moved away from this for high-risk patients. If you have had a fragility fracture, have a T-score at or below -3.0, or have other markers of very high fracture risk, anabolic-first therapy is guideline-supported as the starting point, not a second-line option.
Insurance prior authorization may still ask about prior bisphosphonate use as a coverage criterion, which is a coverage question, not a clinical one. A specialist can document the clinical rationale for anabolic-first in high-risk patients in a way that satisfies the prior authorization requirement without requiring you to actually take bisphosphonates first. Know the difference between what your insurer requires for coverage and what the clinical guidelines say about appropriate treatment.
My DEXA scan shows osteopenia, not osteoporosis. Can I still get teriparatide?
If you have had a fragility fracture, yes, the T-score alone does not determine your risk category. A DEXA scan showing osteopenia (T-score between -1.0 and -2.5) means lower bone density than average but not at the diagnostic threshold for osteoporosis by scan criteria. However, a fragility fracture, a fracture from low-level trauma or no trauma, overrides the T-score in clinical risk assessment.
Current guidelines recognize clinical osteoporosis based on fracture history even when the DEXA T-score is in the osteopenia range. If your femoral neck or other site T-score is in the lower end of the osteopenia range and you have a fragility fracture, you may qualify for anabolic therapy under high or very high fracture risk criteria. This is a conversation to have with an endocrinologist or rheumatologist who can apply the full clinical picture rather than the scan number alone.
What are the real side effects of teriparatide I should know about?
The common and manageable ones first: transient hypercalcemia (temporary elevated blood calcium after injection, usually asymptomatic but can cause nausea or headache), orthostatic hypotension particularly after the first few doses (dizziness when standing, sit or lie down for 15 minutes after initial injections), leg cramps, nausea, and injection-site reactions including redness and mild pain.
The one that gets the most attention: osteosarcoma risk. This comes from rat studies showing osteosarcoma at very high doses over the animals' lifetimes. In humans at clinical doses over the 2-year treatment period, no increased osteosarcoma incidence has been documented. The FDA black box warning exists because of the animal data, not human evidence of harm. The risk is real in principle and unknown in practice at clinical doses, which is why the 2-year cap exists as a precaution.
The practical side effect most people find most challenging is the daily injection requirement. It is a small subcutaneous injection with a prefilled pen, similar to an insulin pen. Most people adapt quickly but adherence over 2 years requires commitment that oral weekly bisphosphonate therapy does not.
What happens after teriparatide? Can I just stop?
Do not stop without transitioning to an antiresorptive agent. This is the most important practical point about teriparatide that many patients are not clearly told at the start. The bone density gains from teriparatide are real and significant, but they are not permanent if treatment stops without a follow-on medication.
After completing the 2-year teriparatide course, transitioning to a bisphosphonate (typically alendronate or zoledronic acid) or denosumab locks in the gains made during anabolic therapy and continues to add protection against bone loss. Studies show that patients who complete teriparatide and then take a bisphosphonate maintain and extend their bone density improvements. Patients who stop without a follow-on lose a significant portion of their gains within 1 to 2 years.
The sequence should be planned before starting teriparatide, not figured out at the 2-year mark. Know what comes next before you begin.
Are bisphosphonates actually dangerous? I have heard about jaw problems and unusual fractures.
The risks are real but rare and largely dose-duration dependent. Two adverse effects get the most attention:
Osteonecrosis of the jaw (ONJ): death of jaw bone tissue, most commonly following dental procedures in people on bisphosphonates. Risk is very low in people taking oral bisphosphonates for osteoporosis at standard doses (estimated at 1 in 10,000 to 1 in 100,000 patients). Risk is significantly higher in people on high-dose IV bisphosphonates for cancer treatment. For osteoporosis patients, the practical implication is: inform your dentist that you take a bisphosphonate before any invasive dental procedure, and discuss whether a drug holiday before the procedure is appropriate.
Atypical femoral fractures (AFF): unusual fractures of the femur shaft, often occurring with minimal trauma, associated with long-term bisphosphonate use (typically more than 5 years). These are rare (estimated at 3 to 50 per 100,000 patient-years depending on duration) but important to know about because they can present as prodromal thigh pain before fracture. Reporting new thigh or groin pain to your prescriber during bisphosphonate therapy is important for this reason.
Both risks increase with duration of use, which is why current guidelines recommend reassessing the need for continued bisphosphonate therapy at 3 to 5 years rather than treating indefinitely. A drug holiday may be appropriate for lower-risk patients after 5 years.
I am active and lift weights. Does exercise change what medication I need?
Exercise is the most underutilized intervention in bone health and it works through a completely different mechanism than any medication. Resistance training and weight-bearing activity stimulate osteoblast activity directly through mechanical loading. Studies consistently show that progressive resistance training increases bone mineral density at the hip and spine, improves bone microarchitecture beyond what density scans capture, and reduces fall risk through improved muscle strength and balance.
Exercise does not replace pharmacological treatment for established osteoporosis or after a fragility fracture, but it is genuinely additive and not just preventive. Someone who is already active and lifting weights is in a meaningfully better position than someone who is not, both because their bones are getting ongoing mechanical stimulation and because their fall risk is lower. This should factor into the conversation with your prescriber about treatment intensity and goal-setting.
For someone already exercising who also needs medication: the combination is better than either alone. Do not let an active lifestyle be used as a reason to delay appropriate pharmacological treatment if your risk profile warrants it.
The MAP Tool follows the thread through your history, your labs, and your symptoms until it finds something real to work with.
Start Your Map